Clinical Trials in Spain / NCT07790666
Recruiting
Observational
Activia Kefir Consumption in Real-world Setting
NCT07790666 · tracked via the Priya Life Science Spain tracker
Condition(s) studied
Kefir Usual Consumers and New Kefir Consumers
Investigational drug(s) / intervention(s)
Commercialized dairy product consumption and stool samples collection
Commercialized dairy product consumption and stool samples collection: Consumption of 280 mL (1 bottle) Activia Kefir drinkable per day during the two-weeks study period and collection of 2 stools samples using a collection kit at participant's home (before and after product consumption)
Study summary
The study aims at generating first real-world insights into how consumers perceive the benefits of consuming Activia Kefir on their digestive wellbeing, overall wellbeing, and to explore its potential effects on the gut microbiome.
Eligibility
Inclusion Criteria:
1. Males and females aged 18 years and older at the time of screening;
2. Willingness to consume Activia Kefir and complete the requested questionnaires;
3. Living in the designated locations in Spain, able to read and write in Spanish;
4. Have a personal electronic device compatible and connectable to internet (i.e., computer, laptop, smartphone) to fill the questionnaires;
5. Signed informed consent.
Exclusion Criteria:
1. People that currently participate in another study with (dairy) investigational or marketed products;
2. Severely immunocompromised individuals (e.g., post-transplant, advanced HIV/AIDS, undergoing chemotherapy);
3. Individuals with known allergies or intolerances to product ingredients. For lactose maldigestion, kefir may improve tolerance, so individuals who are aware of their condition and still wish to participate can be included.
Primary outcome measure(s)
- Gastrointestinal (GI)-wellbeing (single-item question) — After 2 weeks of study product consumption
Difference between after consumption and baseline - Stool consistency (Bristol stool scale, single-item) — After 2 weeks of study product consumption
Difference between after consumption and baseline - Stool frequency (number of stools/week, single-item) — After 2 weeks of study product consumption
Difference between after consumption and baseline - Digestive symptoms frequency questionnaire (DSFQ, frequency of 4 symptoms: abdominal pain/discomfort, bloating, flatulence, borborygmi) — After 2 weeks of study product consumption
Difference between after consumption and baseline
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| Mmr Research Worlwide B.V | Barcelona | Spain | Recruiting |
| Mmr Research Worlwide B.V | Madrid | Spain | Recruiting |
| Mmr Research Worlwide B.V | Valencia | Spain | Recruiting |
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07790666 on ClinicalTrials.gov ↗ ← All trials in Spain